-
Novo Nordisk Partners with Flagship Pioneering for Development of Novel Obesity Treatments
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced a partnership with life sciences venture capital company Flagship Pioneering and its pharmaceutical division, Metaphore Biotechnologies. The collaboration aims to develop up to two glucagon-like peptide-1 (GLP-1) receptor-targeting long-acting treatments for obesity. As per the agreement, Metaphore Biotechnologies will be responsible…
